<DOC>
	<DOCNO>NCT00674817</DOCNO>
	<brief_summary>GSK961081 potent dual pharmacophore demonstrate antimuscarinic beta-agonist pharmacology preclinical study , pharmacology long duration . If reproduce man , GSK961081 potential deliver medicine give daily . The bronchodilatation inhalation single dos GSK961081 alone presence short act beta agonist salbutamol short act muscarinic antagonist , ipratropium bromide measure study . Any residual bronchodilatation post-inhalation GSK961081 demonstrate addition salbutamol ipratropium bromide may provide indirect assessment beta-agonist antimuscarinic component GSK961081</brief_summary>
	<brief_title>An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs .</brief_title>
	<detailed_description>GSK961081 potent dual pharmacophore demonstrate antimuscarinic beta-agonist pharmacology preclinical study , pharmacology long duration . If reproduce man , GSK961081 potential deliver medicine give daily . The bronchodilatation inhalation single dos GSK961081 alone presence short act beta agonist salbutamol short act muscarinic antagonist , ipratropium bromide measure study . Any residual bronchodilatation post-inhalation GSK961081 demonstrate addition salbutamol ipratropium bromide may provide indirect assessment beta-agonist antimuscarinic component GSK961081</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Subject male female ( nonchild bear potential ) ≥ 40 year age ≤ 75 year age . Non child bear potential define physiologically incapable become pregnant , include female postmenopausal ( 2 year without menses appropriate clinical history i.e . age , history vasomotor symptomsestradiol FSH level may check indicate ) female surgically sterile ( hysterectomy , tubal ligation bilateral oophorectomy ) . Subject diagnose COPD accordance ATS/ERS guideline ( per protocol ) . Subject smoker exsmoker history least 10 pack year ( 1 pack year = 20 cigarette smoke per day 1 year equivalent ) Subject FEV1/FVC &lt; 0.7 postbronchodilator ( salbutamol ) Subject FEV1 &lt; 80 % predict normal height , age , gender inhalation salbutamol Response ipatropium bromide define : Either increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 80 µg ipratopium bromide ( Atrovent MDI via spacer ) screen visit Or : documented increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 80 µg ipratopium bromide within 6 month screen increase FEV1 &gt; 6 % &gt; 100 mL within 2h follow inhalation 80 µg ipratopium bromide ( Atrovent MDI via spacer ) screen visit ( order allow potential fluctuation response ipratropium bromide patient know responder ipratropium bromide ) Response salbutamol define : Either increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 400 µg salbutamol MDI ( via spacer ) screen visit Or : documented increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 400 µg salbutamol MDI within 6 month screen increase FEV1 &gt; 6 % &gt; 100 mL within 2h follow inhalation 400 µg salbutamol MDI ( via spacer ) screen visit ( order allow potential fluctuation response salbutamol patient know responder salbutamol ) Body mass index ( BMI ) within range 1835 kg/m2 Subject able willing give write informed consent take part study . Subject available complete study assessment Subjects past present disease , judge Investigator medical monitor may affect outcome study safety subject Subjects clinically relevant finding laboratory safety test . Subjects laboratory value outside reference range may include study Investigator medical monitor agree finding would put subject risk interfere objective study Women pregnant lactate An unwillingness subject abstain sexual intercourse pregnant lactating woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 90 day postdose The subject positive urine drug abuse screen . A minimum list drug screen include amphetamine , barbituates , cocaine , opiates , cannabinoids benzodiazepine . A history , suspect history , alcohol abuse within 6 month screen visit . A positive test hepatitis C antibody , hepatitis B surface antigen , HIV . The subject participate clinical study another New Chemical Entity within past 2 month participate clinical study drug previous month . The subject donate unit blood within 56 day dose intend donate within 56 day complete study . Subject FEV1 &lt; 40 % predicted age , height gender inhalation salbutamol . The subject diagnosis active tuberculosis , lung cancer , sarcoidosis , bronchiectasis , lung fibrosis , pulmonary hypertension primary diagnosis asthma The subject know allergy hypersensitivity ipratropium bromide , salbutamol , lactose A subject ipratropium bromide salbutamol contraindicate Subjects lung volume reduction surgery within 12 month screen Poorly control COPD define : Either : acute worsen COPD manage subject home treatment increase corticosteroid antibiotic 6 week screen Or : 2 exacerbation previous 12 month screen required course oral steroid antibiotic , and/or require hospitalisation Subject respiratory tract infection 4 week screen Subject require treatment inhaled cromolyn sodium , theophyline , oral ß2 agonist , nebulised anticholinergic leukotriene antagonist Subject unable abstain long act ß2agonist 72 hour screen throughout dose period Subject unable abstain tiotropium bromide 28 day screen throughout dose period Subject predict unable abstain short act inhaled ß2agonists short act antimuscarinics 6 hour screen 6 hour dose GSK961081 postdose lung function test complete give study day . Subject receive oral corticosteroid within 6 week screen Subject receive &gt; 1000 µg FP ( equivalent ) day inhale corticosteroid change dose within 6 week screen predict able maintain constant dose study Subject receive oxygen therapy nocturnal positive pressure treatment Medical diagnosis narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction opinion study investigator would prevent use inhaled anticholinergic The subject unable use dose device ( MDPI/ MDI/ spacer ) correctly . Subject carcinoma complete remission least 5 year ( exception carcinoma situ cervix , squamous cell carcinoma basal cell carcinoma subject consider cure ) A history congestive heart failure , coronary insufficiency cardiac arrhythmia find screen 24h Holter monitor would contraindicate subject 's participation study 12 lead ECG abnormality either clinically significant may interfere QTc measurement QTc &gt; 450 msec PR interval outside range 120 220 msec . A supine mean heart rate outside range 4090 bpm screen . Persistently elevate supine blood pressure high 160/95 screening . Subject receive highdose diuretic and/ ß2adrenergic antagonist Subject serum potassium level reference range screening . Inability understand protocol requirement , instruction studyrelated restriction ; nature , scope possible consequence study . Unlikely complete study ; e.g. , uncooperative attitude , inability return followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>salbutamol ,</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>GSK961081 muscarinic receptor antagonist ,</keyword>
	<keyword>COPD</keyword>
	<keyword>ipratropium bromide ,</keyword>
	<keyword>Asthma</keyword>
	<keyword>ß2-adrenergic agonist ,</keyword>
</DOC>